Soc. Generale Call 25 AOMD 20.09..../ DE000SW13K54 /
13/05/2024 21:46:33 | Var.+0.004 | Denaro21:59:09 | Lettera21:59:09 | Sottostante | Prezzo di esercizio | Expiration date | Tipo di opzione |
---|---|---|---|---|---|---|---|
0.039EUR | +11.43% | 0.040 Quantità in denaro: 20,000 |
0.050 Quantità in lettera: 20,000 |
ALSTOM S.A. INH. ... | 25.00 EUR | 20/09/2024 | Call |
GlobeNewswire
06:00
SPEE3D LAUNCHES EXPEDITIONARY MANUFACTURING UNIT (EMU) – THE COMPLETE MOBILE ADDITIVE MANUFACTURING ...
GlobeNewswire
05:01
MKS Instruments Announces Pricing of Upsized Private Offering of $1.2 Billion of 1.25% Convertible S...
GlobeNewswire
04:10
Kilmer Sports Ventures Enters into Exclusive Negotiations to Acquire French Professional Football Cl...
GlobeNewswire
03:50
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
03:00
Infinera to Announce Preliminary Fiscal First Quarter 2024 Financial Results on May 14, 2024
GlobeNewswire
03:00
GLOBAL LIFE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Bee...
GlobeNewswire
02:29
AKRO INVESTOR ALERT: Edelson Lechtzin LLP Urges Akero Therapeutics, Inc. (NASDAQ: AKRO) Shareholders...
GlobeNewswire
02:06
MBUU INVESTOR ALERT: Edelson Lechtzin LLP Urges Malibu Boats, Inc. (NASDAQ: MBUU) Shareholders With ...
GlobeNewswire
02:00
ROSEN, A LEADING LAW FIRM, Encourages Rivian Automotive, Inc. Investors With Losses in Excess of $10...
GlobeNewswire
02:00
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- an...
GlobeNewswire
02:00
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatme...